Research Suggests Dementia Epidemic Overplayed: Should Companies Rethink Strategy?
This article was originally published in Scrip
Executive Summary
Contrary to expectations of a "dementia epidemic", a new study has found that the number of cases in some western European countries seems to be stabilizing, if not decreasing, thanks to better living standards and management of vascular and chronic diseases. Companies investing in expensive and elusive dementia breakthroughs may be disheartened to hear the review's lead author caution against "the current overemphasis on diagnostics and drug interventions".
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.